Search results
27 wrz 2023 · Dr Matthew Wheater from the University Hospital Southampton gives us a update on the revised uveal melanoma guidelines & an overview on how ocular melanoma can be treated. When producing a...
On October 3, 2023, we held a special webinar about the latest FDA-approved drug for metastatic uveal melanoma: melphalan delivered directly to the liver featuring Dr. Marlana Orloff,...
AIOS International Webinar on Ocular Oncology - What New am I Doing in 2020Topic - Key Note: Uveal Melanoma 2020 Speaker Dr Carol L Shields. ... Uveal Melanoma 2020 Speaker Dr Carol L Shields ...
15 sie 2023 · FDA approves melphalan as a liver-directed treatment for uveal melanoma. On August 14, 2023, the Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery...
28 lip 2023 · The FDA granted orphan drug designation to darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C (PKC), for the treatment of uveal melanoma, on 2 May 2022. Primary uveal melanoma has a high risk of progressing to metastatic uveal melanoma, with a poor prognosis.
21 sie 2023 · The Hepzato Kit (melphalan /Hepatic Delivery System) is used to treat metastatic uveal melanoma (mUM) that has hepatic metastasis. The Hepzato Kit delivers melphalan, a long-approved chemotherapy treatment, directly to the liver through a novel device delivery system called the Hepatic Delivery System (HDS).
15 sie 2023 · On August 14, 2023, the Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System) containing melphalan (HEPZATO, Delcath Systems, Inc.) as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic ...
